MAP2K1 and neoplasm: By examining MAP2K1 mutations more broadly by standard Sanger protocols, the overall frequency of mutations in MAP2K1 was identified as 48% in a panel of HCLv/HCLc-IGHV4-34 tumours (n = 21) [13].